argentum nitricum golyócskák
dr. peithner kg gmbh&co -
argentum nitricum golyócskák
remedia homöopathie gmbh -
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - egyéb daganatellenes szerek - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
pelacur belsőleges cseppek
cassella-med gmbh & co.kg - muskátli gyökér tinktúra -
kaloba 20 mg filmtabletta
dr. willmar schwabe gmbh&co. kg - muskátli gyökér -
kaloba szirup
dr. willmar schwabe gmbh&co. kg - muskátli gyökér -
peloid belsőleges cseppek
pharmaselect gmbh - muskátli gyökér - cough and cold preparations
dulcamara s phcp golyócskák
phönix lab. gmbh - schuster szállás metallicum ; atropa belladonna -
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - daganatellenes szerek - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - daganatellenes szerek - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.